The American Diabetes Association provides collaborative support for large, independently-funded research initiatives strategically aligned with the Association’s mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
American Diabetes Association co-support is intended to be supplemental to existing funding; all projects considered for co-support must have significant independent funding from governmental agencies, non-profit organizations or multi-party collaborative groups.
Additional information on initiatives that the Association supports through this mechanism is listed below.
Type 1 Diabetes TrialNet is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes.
GRADE is a comparative effectiveness study looking at what medications work best at lowering blood glucose levels in patients who are newly diagnosed with diabetes.
The Restoring Insulin Secretion study (RISE) includes 3 studies examining whether aggressive glucose lowering will lead to recovery of pancreas function in those with prediabetes and early type 2 diabetes.
The goal of the Vitamin D and type 2 diabetes (D2d) study is to determine whether vitamin D supplementation is safe and effective in delaying the onset of type 2 diabetes in people at risk for the disease, and to gain a better understanding of how vitamin D affects glucose metabolism.
Accelerating Medicines Partnership
The Accelerating Medicines Partnership (AMP) is a bold new venture between the NIH, non-profit organizations and biopharmaceutical companies to transform the current model for developing new diagnostics and treatments. By jointly identifying and validating promising biological targets of disease, the partnership strives to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.
FNIH Biomarkers Consortium
The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.
|Collaborative Co-Support Award
|Not currently accepting applications
|Research projects considered for co-support may include any basic or clinical research relevant to diabetes and diabetes-related disease states, or projects for the development of public research resources (databases, sample collections, etc.) relevant to diabetes research.
||Awards provide up to $1,000,000 per year for up to three years. Up to 10% of total costs for yearly PI salary support and up to 15% for indirect costs may be requested.